Magnify Education | |
175 W Canyon Crest Rd, Suite 305, Alpine, UT 84004-2010 | |
(801) 910-3957 | |
Not Available |
Full Name | Magnify Education |
---|---|
Type | Facility |
Speciality | Optometrist |
Location | 175 W Canyon Crest Rd, Alpine, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205381860 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | 90422859934 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Magnify Education 175 W Canyon Crest Rd, Suite 305, Alpine, UT 84004-2010 Ph: (801) 910-3957 | Magnify Education 175 W Canyon Crest Rd, Suite 305, Alpine, UT 84004-2010 Ph: (801) 910-3957 |
News Archive
By studying the sick hearts removed from four patients undergoing heart transplants, researchers have identified a protein and a signaling pathway that may contribute to sudden death in an inherited form of heart disease.
VitaPath Genetics, the Spina Bifida Association and the National Council on Folic Acid today announced the launch of the free iPhone application—the VitaTrack Folate Tracker— which allows women to track their daily intake of folate and folic acid. Maintaining an adequate level of folic acid prior to and during pregnancy can reduce the risk of serious birth defects like Spina Bifida by up to 70%. Studies show that folic acid may also help prevent congenital heart disease, pre-term labor, and cleft lip and palate.
Steve Larsen, director of the federal Center for Consumer Information and Insurance Oversight, is leaving his post to join UnitedHealth as an executive vice president, sparking speculation on the move.
A new study has found that one in every six persons diagnosed with HIV is over the age of 50 years. This new study was published yesterday (26th September 2017) in the journal Lancet HIV.
TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016.
› Verified 4 days ago